Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Taspoglutide
Overview
Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from human GLP-1 with amino acid substitutions designed to resist dipeptidyl peptidase-4 degradation and extend duration of action. The peptide activates pancreatic GLP-1 receptors to promote glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying.
Mechanism of Action
Its structural modifications were intended to support once-weekly administration for the treatment of type 2 diabetes mellitus.
Research Summary & Key Findings
Phase 3 clinical trials (T-emerge program) demonstrated efficacy in glycemic control and weight reduction, with results published in Diabetes Care and related journals between 2010 and 2011. Development was discontinued in 2010 due to concerns over injection site reactions and gastrointestinal tolerability despite meeting primary efficacy endpoints, and the compound never received regulatory approval.
Clinical Status
Taspoglutide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Taspoglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Taspoglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Taspoglutide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsNo lawful pathway today
Taspoglutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.